Editors-in-Chief. Associate Editors
|
|
|
- Sharlene McKenzie
- 6 years ago
- Views:
Transcription
1 Editors-in-Chief C. Warren Olanow AdHoc IEC as Journal Editor The Mount Sinai School of Medicine Consultant: AbbVie, Novartis/Orion, Teva/Lundbeck, Ceregene Ownership Interest: Stock: Clintrex - (consults for AstraZeneca, Novartis, Synagile, Phytopharm, Biotie (UBC), Civitas, Lundbeck, Siena, Werina, US World Med, Pharma 2B, Intec, Medivation, Upsher Smitn) Other: Professor of Neurology and Neuroscience: Mount Sinai School of Medicine, Visiting Professor: UCSF, Editor in Chief: Western Hemisphere Movement Disorders Journal Michael J Fox Foundation: Executive Committee World Parkinson Congress: Executive Committee Jose Obeso AdHoc IEC as Journal Editor University of Navarra Consultant: Has served in the Advisory Board of GSK (UK), and received honorarium for lecturing in meetings organized by GSK (Spain), Lundbeck-TEVA and UCB. Grants: Funding from Spanish Science and Education Ministery and European Union (REPLACES) Salary: University of Navarra Associate Editors Erwan Bezard Consultant: Motac Neuroscience (UK) Grants/ Research Support: Framework Program 7, Agence National de la Recherche, Michael J Fox Foundation, Foundation de France, Cariplo Foundation, France Parkinson, Institut de Recherche en Sante du Canada Ownership Interest: Motac Holding (UK), Plenitudes SARL (France)
2 Kailash Bhatia IEC Member Institute of Neurology Grants: Beneficiary of unrestricted research grants from Ipsen, Allergan, UCB, Merz and GSK. Honoraria: Have received honoraria from Ipsen, Allergan, Merz, GSK, to attend meetings and for giving lectures or chairing meetings Royalty: Book Royalties from Oxford University Press David John Burn IEC Member & Incoming Treasurer-Elect per 2013 Election Newcastle University Consultant: GSK Grants: Michael J Fox Foundation, Parkinson's UK, Wellcome Trust, NIHR- HTA Honoraria: Teva-Lundbeck, UCB, Genus Christine Klein Task Force Genetic Movement Disorders Medical University of Luebeck Consultant: Centogene Grants: Possehl Foundation, European Commission (EU), German Research Foundation (DFG), Federal Ministry of Education and Research, Hermann and Lilly Schilling Foundation and Stifterverband fur die Deutsche Wissenschaft, Dystonia Coalition (NINDS), Bachmann Strau Honoraria: Orion Pharma Connie Marras Task Force Genetic MDs Toronto Western Hospital
3 Antonio Strafella Grants: Canadian Institute Health Research (CIHR), Canadian Foundation Innovation (CFI), Canada Parkinson's Society, National Parkinson Foundation, Parkinson Disease Foundation, Tourette Syndrome Association, E.J. Safra Foundation, Ontario Gambling Research Centre, Canada Research Chair Program. Assistant Editors Manuel Alegre Alberto Espay Consultant: Solvay/ Abbvie, Chelsea Therapeutics, TEVA, Impax, Merz, Solstice Neurosciences, Eli Lilly, USWorldMeds Grants: NIH (1K23MH092735), CleveMed/ Great Lakes Neurotechnologies, and Michael J Fox Foundation Honoraria: UCB, Novartis, Movement Disorders Society, TEVA, American Academy of Neurology Royalty: Lippincott Williams & Wilkins, Cambridge Other Ownership Interest: None Mark Edwards Grants: NHR, Guarantors of Brain, UK Dustonia Society, Parkinson s UK, Bachmann Strauss Foundation Honoraria: For speaking from UCB, Novartis, and Movement Disorder Society Royalty: From the Oxford University Press for The Oxford Specialist Handbook of Parkinson s Disease and Other Movement Disorders Salary: University College London Clinical Vignette Editor Steven Frucht Consultant: Mer3
4 Honoraria: Neurology & Movement Disorders Society. I do not have any relevant organizational or other interests to disclose. Medical Images Thomas Naidich International Editorial Board Maren Bodden Paolo Calabresi Grants/ Research Support: Bayer Schering, Biogen, Boehringer Ingelheim, Eisai, Merck Sharp & Dohme, Novartis, Lundbeck, Sanofi-Aventis, Sigma Tau, and UCB Pharma and from Ricerca Corrente IRCCS, Ricerca Finalizzata IRCCS (European Community Grants SYNSCAFF and Replaces), the Italian Minister of Health and AIFA (Agenzia Italiana del Farmaco). Other: Dr. Calabresi serves as an editorial member of Lancet Neurology, the Journal of Neuroscience, Movement Disorders and Synapse Christopher Coffey Consultant: ZZ Biotech, LLC Grants: Michael J Fox Foundation Brian Day Grants: Medical Research Council Salary: University College London I do not have any relevant organizational or other interests to disclose. Bogdan Draganski
5 John Duda MD Philadelphia VA Medical Center Ownership Interest: I own common stock in General Electric. Lewy Body Dementia Association- Scientific Advisory Board Member Mark Edwards Consultant: None Grants: NIHR, Guarantors of Brain, UK Dystonia Society, Parkinson s UK, Bachmann Strauss Foundation Honoraria: For speaking from UCB, Novartis, Movement Disorder Society Salary: University College London Other Ownership Interest: None Susan Fox IEC Member University of Toronto, Toronto Western Hospital Consultant: Allergan,Serono,Merz,Teva,Merck Serono, Grants: Parkinson Society Canada, Dystonia Medical Research Foundation (DMRF); Michael J Fox Foundation, Canadian Institutes of Health Research (CIHR) Honoraria: Atuka, Novartis, Teva, Merck Serono Salary: UHN Practice plan WFN: Fundraising Committee PSG: Class Motor Group Committee Member Marwan Hariz Grants: St jude Honoraria: Occasionally from Medtronic, stjude Other: Occasional travel expenses to meetings by St Jude and Medtronic Nobutaka Hattori Consultant: Hisamitsu Pharmaceutical Grants/ Research Support: Otsuka Pharmaceutical, Boehringer Ingelheim, Kyowa Hakko-Kirin Pharmaceutical Company
6 Other Interests/ Organizational Interest Disclosure: American Neurological Association- Corresponding fellow, Societas Neurologica Japonica- Director, the Japanese Society of Mitochdrial Research and Medicine- Director, Movement Disorders Society Japan- Executive Committee, The Japanese Academy of Home Care Physicians- Director, The Japanese Society of Neurological Therapeutics- Councilor, Japanese Society of Apheresis- Councilor, Japan Parkinson Disease Association- Adviser Robert Hauser Honoraria: Med-IQ; UCB Pharma, Inc.; UCB, Inc.; AstraZeneca, Ltd.; Ceregene; Biotie. Consultant: Abbvie; Adamas; Allergan Inc.; Chelsea Therapeutics, Inc.; GE Healthcare, Ipsen Biopharmaceuticals, Inc.: Merck/ MSD Corp.; Noven Pharmaceuticals; TEVA Neuroscience, Inc.; TEVA Pharmaceuticals, Ltd.: Zanbon Company, SpA. Other Advisory Boards: Straken Pharmaceuticals; Targacept, Inc; Upsher- Smith Laboratories; Lundbeck; Impax Laboratories; GLG Research; Eily Lily. Paul Krack Stephane Lehericy Grants: Pfizer, Servier Simon Lewis Andres Lozano Colum MacKinnon Name of Organization: National Institute of Health (NIH)
7 Volunteer Position: Ad-hoc study section reviewer. Mike McDermott Consultant: Bioness, Inc.; Biotie Therapies Corporation; Asubio Pharmaceuticals, Inc.; Isis Pharmaceuticals; Biogen Idec, Inc. I do not have any relevant organizational or other interests to disclose. Erwin Montgomery Consultant: FHC, Inc. Grants/ Research Support: Dystonia Research fund- University of Alabama at Birmingham Movement Disorders Research fund- University of Alabama at Birmingham Intellectual Property Rights: n-dimensional unsupervised cluster analysis- licensed to Intel intraventricular anode- licensed to Intel Royalty: Oxford University Press- Deep Brain Stimulation Programming: Principles and Practice Salary: University of Alabama at Birmingham, University of Alabama Health Services Foundation, Birmingham Veterans Affairs Medical Center, Greenville Neuromodulation Center Ron Postuma Task Force Define PD Montreal General Hospital Consultant: Canadian Institute of Health Research, Fonds de la Recherche en sante Quebec, Webster Foundsation Grants: Novartis Canada, Teva Canada, Allergan Canada Royalty: Fonds de la Recherche en Sante Quebec Ralf Reilmann University of Muenster Consultant: Cure Huntington's Disease Initiative Foundation, Ipsen, Lundbeck, Meda Pharma, Neurosearch, Novartis, Pfizer, Siena Biotech, Temmler, Teva Grants: CHDI Foundation, High-Q-Foundation, EHDN, DFG, EU-FP7 Honoraria: AOP-Orphan, Bayer, Temmler Intellectual Property Rights: Quantitative motor assessments Lynn Rochester Consultant: I have given a lecture based upon my research to GSK, Medical Research Council, National Institute for Health Research (HTA; BRU; BRC),
8 Welcome Trust, Michael J Fox, Parkinson s UK, EU framework 7, GSK. Maria Rodriquez-Oroz Consultant: Luudbeck, UCB Webster Ross Susanne Schneider Neurology University of Kiel, Germany Consultant: None Grants: Else Kröner- Fresenius Stiftung; Eva Luise und Horst Köhler Stiftung, Novartis Pharma Honoraria: None Salary: University of Kiel Other Ownership Interest: None Andrew Singleton David Standaert M.D., PhD University of Alabama at Birmingham Consultant: Abbvie (Abbott Laboratories), Teva Neurosciences, Serina Therapeutics, Lundbeck Grants: Abbvie Royalty: McGraw Hill Publishers Other Interests: American Parkinson Disease Association-Chair, Scientific Advisory Board; Bachmann-Strauss Dystonia Parkinson Foundation; Michael J. Fox Foundation- Scientific Advisory Board
9 Fabrizio Stocchi Archives Committee Chair IRCCS San Raffaele Pisana Roma Ryosuke Takahashi Consultant: KAN Research Institute, Inc., Daiichi-Sankyo Grants: Dainippon Sumitomo Pharma, Boehringer Ingelheim, Novartis, Pfizer Co. Ltd., Glaxo Smith Kline, Takeda Pharmaceutical Company, Mitsubishi Tanabe Pharma, Kyowa Hakko Kirin Co. Honoraria: Boehringer Ingelheim, FP Pharmaceutical Corp., Glaxo Smith Kline, Dainippon Sumitomo Pharma, Medical Review, Novartis, Daiichi- Sankyo, Kyowa Hakko Kirin Co., Mitsubishi Tanabe Pharma, Eisai Co. Ltd., Nihon Pharmaceutical Co., Otsuka Pharmaceutical Co., Janssen Pharmaceutical Co., Sanofi, Alfresa Pharma Co., Japan Brood Products Organization, ASBIO PHARMA CO., MSD Enza Valente Grants: European Community, European Research Council, Italian Ministry of Health, Italian Ministry of University and Research, Telethon Foundation Italy Honoraria: Lundbeck Josep Valls-Sole Daniel Weintraub Consultant: Teva Pharmaceuticals, Lundbeck Inc., Pfizer, Avanir Pharmaceuticals, Merck & Co., UCB, Bristol-Myers Squibb Company, Novartis Pharmaceuticals, Eli Lilly and Company, Clintrex LLC Grants: Novartis, Medtronic, Elan Honoraria: Teva
Dustin A. Heldman 1, Alberto J. Espay 2, Peter A. LeWitt 3, and Joseph P. Giuffrida 1
Dustin A. Heldman 1, Alberto J. Espay 2, Peter A. LeWitt 3, and Joseph P. Giuffrida 1 1.Great Lakes NeuroTechnologies 2.The University of Cincinnati 3.Henry Ford Health System Disclosures Dr. Heldman received
EFFECT OF PRIDOPIDINE ON MOTOR FUNCTION IN PATIENTS WITH HUNTINGTON DISEASE: RESULTS FROM THE HART STUDY
EFFECT OF PRIDOPIDINE ON MOTOR FUNCTION IN PATIENTS WITH HUNTINGTON DISEASE: RESULTS FROM THE HART STUDY HSG HART Investigators Presented by Karl Kieburtz, MD, MPH Director, Center for Human Experimental
Editorial Team Conflict of Interest Statements
Editorial Team Conflict of Interest Statements Editor in Chief David Dodick Advisory board/consultant: Allergan, Amgen, Alder, Arteaus, Pfizer, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies,
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
DLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd
THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd Disclosures Associate Professor in the Alzheimer Center at the VU
TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
NAME CTS AFFILIATION DISCLOSURE UPDATED
NAME CTS AFFILIATION DISCLOSURE UPDATED Darcy Marciniuk (Chair) and Canadian and Canadian COPD Alliance Consultant Fee, Speaker s Bureau, Advisory Committee: AstraZeneca, Boehringer-Ingelheim, Canadian
Stroke and Headache Headache and Stroke
Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin
Quality Indicators in Chronic Pain Management
Disclosures (2008-2013): 1. Employment: Heidelberg University 2. Advisor: Allergan, Astellas, Astra-Zeneca, Boehringer Ingelheim, Galderma, Glaxo Smith Kline, Grünenthal, Lilly, Merz, Merck-Sharpe & Dohme,
Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
Patient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
Organizational, or Other Financial Benefit None None None None None None. None None None None None None
Comprehensive Relationships With Industry and Other Entities AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non ST-Elevation Myocardial Infarction Measures Committee Jneid Hani, Chair Baylor
DRAFT SLIDES. Michael Huss Child and Adolescent Psychiatry, Johannes Gutenberg University Mainz, Mainz, Germany
DRAFT SLIDES Separating efficacy and sedative effects of guanfacine extended release in children and adolescents with ADHD from four randomized, controlled, phase 3 clinical trials Michael Huss Child and
SUPPLEMENTARY DATA. Telediab Study Group :
Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète
Membership of cirrhosis guideline Committee
Membership of cirrhosis guideline Committee The Committee will operate as an advisory Committee to NICE s Board, developing a guideline on cirrhosis. The terms of reference and standing orders for the
John Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
The Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
CJASN Editorial Team Disclosures 2018
CJASN Editorial Team Disclosures 2018 Editor in Chief Rajnish Mehrotra, MD, MBBS, FASN Organization Name: University of Washington Current Employer: University of Washington, Seattle, WA Scientific Advisor/Membership:
Supported by an unrestricted educational grant by Merck & Co.
Supported by an unrestricted educational grant by Merck & Co. TABLE OF CONTENTS Agenda & Faculty List...2 Course Description...3 Learning Objectives...3 Accreditation Statement & Credit Designation...3
CURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA
Bruce D. Kohrman, M.D. 12305 SW 69 th Place Miami, Florida 33156 Telephone: (305) 903-8678 Fax: (305) 661-1672 CURRICULUM VITAE EDUCATION 1977 - B.S. Stanford University, Stanford, CA 1982 - M.D. Case
MS Trust Comments on the ACD
MS Trust Comments on the ACD Name xxxxxxxxxxx Role other Other role xxxxxxxxxxxxxxxxxx Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 The MS Trust maintains that
JEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis
5137 First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the Study: An Interim Analysis Kristian Reich, MD 1 ; Stefanie Bomas, MD 2 ; Bernhard Korge, MD 3 ; Maria Manasterski,
A Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
SickKids Research Institute: List of Funders
SickKids Research Institute: List of Funders 2009-2010 Agency Funding $ Agency Funding $ 3M Pharmaceuticals 2,901 International Council on Amino Acid Science 80,800 Abbott Diagnostics 6,639 International
Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer
Saturday, October 27, 2018 7:00 AM - 3:45 PM Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer Program Director John V.
Giancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
Appendix K Declarations of Interests
Appendix K Declarations of Interests Ms Theresa Shaw - Chair, Guideline Development Group Chief Executive, Foundation of Nursing Studies (FoNS), London Funding for the 'Developing Practice for Healthy
75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
Canadian Stroke Best Practice Recommendations STROKE PREVENTION WRITING GROUP 2017:
Canadian Stroke Best Practice Recommendations STROKE PREVENTION WRITING GROUP 2017: NAME PROFESSIONAL ROLE LOCATION DECLARED CONFLICTS OF INTEREST Wein, Theodore Gladstone, David Côté, Robert Berlingieri,
THC:CBD Daily Practice Evidence in MS Spasticity Management: The Moment of Large Databases
THC:CBD Daily Practice Evidence in MS Spasticity Management: The Moment of Large Databases Almirall-Sponsored Satellite Symposium of the 31 st Congress of the European Committee for Treatment and Research
CLINICAL GUIDELINES COMMITTEE September 9-10, 2014 DISCLOSURE OF INTERESTS
CLINICAL GUIDELINES COMMITTEE September 9-10, 2014 DISCLOSURE OF INTERESTS NAME Financial INTERESTS Non-Financial Thomas Denberg, MD, PhD, FACP, Chair Michael J. Barry, MD, MACP Indicate Employment: Carilion
A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
JABLONSKI DEBATES PSA TESTING
The JABLONSKI DEBATES PSA TESTING Getting Prostrate for the Prostate The JABLONSKI DEBATES Learning has never been this much fun (just like walking through a field littered with land mines.) The JABLONSKI
Quality Medical Donations
PQMD members played an active role in relief efforts following devastating floods left by Hurricane s Harvey, Irma, and Maria. PQMD Community of Practice: Connect Convene - Catalyze Are you an engaged
ESMO Symposium on Immuno-Oncology Programme book
IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org
Moving Treatment Earlier Disease Modification in Early PD
Moving Treatment Earlier Disease Modification in Early PD Ron Postuma Montreal General Hospital McGill University Disclosures: - Grants: Fonds de la Recherche en Sante Quebec, Canadian Institute of Health
BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
Abstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry
(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
Membership of Parkinson s disease guideline Committee
Membership of Parkinson s disease guideline Committee The Committee will operate as an advisory Committee to NICE s Board, developing clinical guideline on Parkinson s disease The terms of reference and
EAPCI: Biodegradable Scaffolds-Writers 2016
Baumbach Andreas Byrne Robert - Medicines Company : Drugs (2015) - Abbott Vascular : Stents (2015) - Abbott Vascular : Stent (2015) - Boston Scientific : Medical devices (2015) - Biotronik : Medical devices
Glenmark Pharmaceuticals Inc., USA; Glenmark Pharmaceuticals Ltd., India. Icahn School of Medicine at Mount Sinai, New York, NY, USA;
RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, EXPLORATORY, MULTICENTER STUDY OF IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS Emma Guttman-Yassky, MD, PhD 1 ; Ana B. Pavel,
Journal of the American College of Cardiology
Advertisement Journal of the American College of Cardiology Volume 72, Issue 3, July 2018 DOI: 10.1016/j.jacc.2018.04.063 PDF Article Download Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory
Targets of Psychopharmacological Drug Action
Targets of Psychopharmacological Drug Action (page 33 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry University of California, San Diego School of Medicine Honorary
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
EFSPI Annual Report 2001
EFSPI Annual Report 2001 Highlights Collective comments from the national member associations were submitted to EMEA for four CPMP draft documents and words of thanks were received from EMEA. A position
Apixaban versus Heparin/Vitamin K Antagonist in Anticoagulation-naïve Patients with Atrial Fibrillation Scheduled for Cardioversion: The EMANATE Trial
Apixaban versus Heparin/Vitamin K Antagonist in Anticoagulation-naïve Patients with Atrial Fibrillation Scheduled for Cardioversion: The EMANATE Trial Michael D. Ezekowitz, Professor, Sidney Kimmel Medical
Promius Pharma, a subsidiary of Dr. Reddy s Laboratories, Princeton, NJ; 2 Vedanta Research, Chapel Hill, NC; 3
Triptan Use and Discontinuation Among a Population Sample of Persons with Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study Aftab Alam, MBBS, MS, MBA 1 ; Sagar Munjal, MD 1
Do the Right Thing: Good Clinical Practice for Clinical Research
Do the Right Thing: Good Clinical Practice for Clinical Research Andrew A. Nierenberg, MD Director, Bipolar Clinic and Research Program, Director, Training and Education, MGH Research Institute Massachusetts
nephropathy and/or chronic kidney disease Summary of recommendations
July 2017 Guidelines: Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients
Evidence grades for the recommendations
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy
Roxana Mehran, Dominick J. Angiolillo, Ron Waksman, Joseph M. Sweeny, Ganesh Raveendran, Renli Teng, Yonggang Zhao, Glenn Carlson NCT
Ticagrelor versus Clopidogrel in Troponinnegative Patients with Acute Coronary Syndrome Undergoing Ad-Hoc Percutaneous Coronary Intervention: Results of a Prospective, Randomized, Multicenter Pharmacodynamic
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) account for approximately
Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials
Publishing Staff Senior Vice President of Clinical Affairs Jeff D. Prescott, PharmD, RPh Senior Clinical Projects Manager Ida Delmendo Clinical Projects Manager Tara Petersen Project Christina Doong Quality
Frederick James de la Vega, M.D.
Frederick James de la Vega, M.D. CURRENT PRACTICE 06/2003-present Coastal Neurological Medical Group, Inc. 9850 Genesee Avenue Suite 740 La Jolla, CA 92037 Services: Parkinson s disease, Movement Disorders,
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3 Presentation Number: 290O Lecture Time: 11:18-11:33 Speakers: Peter
Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
Healthcare Professional Information & Patient Information Leaflet (PL)
New concept for the SmPC/ Healthcare Professional Information & Patient Information Leaflet (PL) Fiona Reekie Director Global Regulatory Affairs Johnson & Johnson Pharmaceuticals Group Disclaimer The views
New Prognostic Markers in Acute Myeloid Leukemia (AML)
New Prognostic Markers in Acute Myeloid Leukemia (AML) For more visit ResearchToPractice.com/5MJCMDSAML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes
Key ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism
Key ASH Presentations Issue 5, 2012 SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology
ECMELLA. Associate Prof. Dirk Westermann, MD, PhD. Department of General and Interventional Cardiology Hamburg, Germany. Department of Medicine
ACS in Women ECMELLA Combined Impella and ECMO in Cardiogenic Shock Prof. Peter Clemmensen, MD, DMSc, FESC, FSCAI Associate Prof. Dirk Westermann, MD, PhD University Heart Center Hamburg-Eppendorf Department
Novità in Tema di NOACs Cardioversione Riccardo Cappato, MD
Novità in Tema di NOACs Cardioversione Riccardo Cappato, MD Electrophysiology & Arrhythmia Center IRCCS Humanitas Research Institute, Milan & Gavazzeni Clinics, Bergamo - Italy Disclosure Statement of
ALBERTA PRINCIPAL INVESTIGATORS
ALBERTA PRINCIPAL INVESTIGATORS Dr. Gregory Cairncross is Head of the Department of Clinical Neurosciences at the University of Calgary and holder of the Alberta Cancer Foundation Chair in Brain Tumor
in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy
Biographies. Angelo Antonini. David Brooks
Biographies Angelo Antonini Angelo Antonini joined the Parkinson Institute in Milan, Italy, in 1997 and is now the medical coordinator for Information Technology and Clinical Research at the Department
C-SSRS/KIT version includes. C-SSRS Scoring/ Administration instructions (13pgs)
This is a Sample version of the Columbia-Suicide Severity Rating Scale (C-SSRS) KIT The full version of watermark.. the C-SSRS/KIT comes without sample The full complete C-SSRS/KIT version includes C -SSRS
ICGC launches new project and releases more genomic data on cancer
ICGC launches new project and releases more genomic data on cancer Toronto March 15, 2012. The International Cancer Genome Consortium (ICGC) today announced a new project from South Korea to identify the
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES All individuals able to influence or control content of any CME certified activity that will be presented were required to complete
Stahl s Illustrated. Antidepressants. Stephen M. Stahl. University of California at San Diego. Nancy Muntner. Illustrations. Angela Felker.
Antidepressants Stephen M. Stahl University of California at San Diego Nancy Muntner Illustrations Angela Felker Editor ii PREFACE These books are designed to be fun. All concepts are illustrated by full-color
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
Association of Northern California Oncologists Annual Report
Association of Northern California Oncologists 2017 Annual Report The Association of Northern California Oncologists (ANCO) was organized in 1990 to be an advocate for, educate, and inform the practicing
Adherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
THE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS...
V T THE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS... BRIEF DESCRIPTION The European Brain Council (EBC) is carrying out a new research project for 2015-2017 on The value of treatment
Key ASCO Presentations Issue 4, Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM)
Key ASCO Presentations Issue 4, 2010 Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM) For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF
Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks
Comparison of two HCV-RNA assays assessing early response to simeprevir+pegifn/rbv to select patients suitable to shorten therapy to 12 weeks C Sarrazin, 1 M Buti, 2 C Moreno, 3 M Gschwantler, 4 GR Foster,
Curriculum Vitae: Angelo Antonini, MD, PhD
1 Curriculum Vitae: Angelo Antonini, MD, PhD Date of Birth: August 2, 1961 Place of Birth: Foligno (Perugia) Italy Nationality: Italian Citizen Home Address and Phone: Via Coatit 1b. Padua, Italy Office
Research Article Essential Tremor in the Elderly and Risk for Dementia
Neurodegenerative Diseases, Article ID 328765, 5 pages http://dx.doi.org/10.1155/2014/328765 Research Article Essential Tremor in the Elderly and Risk for Dementia Holly A. Shill, 1 Joseph G. Hentz, 2
VOMITING INTESTINAL GAS CONSTIPATION DIARRHEA TABLE 1 CAUSES OF DIARRHEA GASTROINTESTINAL TRACT WALL DISORDERS...
CHAPTER ONE: INTRODUCTION.1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS...
Simon Stevens Chief Executive
Simon Stevens Chief Executive 01/10/2015 Leeds Internal Meetings 40.14 40.14 01/10/2015 Penrith Visit 124.30 124.30 08/10/2015 Leeds Internal Meetings 133.58 133.58 14/10/2015 Birmingham Speaking Engagement
2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
Program Agenda. 11:45 AM ET Registrants Join the Program Dial-in: (877) Log-in:
Program Agenda Tuesday, January 26, 2016 12:00 PM to 1:00 PM Eastern Time 11:00 AM to 12:00 PM Central Time 10:00 AM to 11:00 AM Mountain Time 9:00 AM to 10:00 AM Pacific Time 11:45 AM ET Registrants Join
Faculty. Course Directors. Liza Blumenfeld, MA, CCC-SLP, BCS-S UC San Diego Health - Speech-Language Pathologist
Faculty Course Directors Liza Blumenfeld, MA, CCC-SLP, BCS-S UC San Diego Health - Speech-Language Pathologist Non-financial Disclosure: Developer of Swallow RehApp Joseph Califano, MD UC San Diego Health
Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
Lonasen (Blonanserin) Lullan (Perospirone) Saphris/Sycrest (Asenapine, ORG 5222, SCH ) Saphris/Sycrest (Continued)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 2 INTENDED AUDIENCE... 2 SCOPE OF REPORT... 3 METHODOLOGY... 3 INFORMATION SOURCES... 4 AUTHOR S CREDENTIALS...
Ovarian Cancer Guideline. Association of Chartered Physiotherapists in Oncology and Palliative Care
Ovarian Cancer Guideline Stakeholder List: A Little Wish Abbott GmbH & Co KG Abbott Laboratories Limited Aberdeen Royal Infirmary Airedale NHS Foundation Trust Almac Diagnostics Anglia cancer network Arden
Key ASCO Presentations Issue 2, Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases
Key ASCO Presentations Issue 2, 2010 Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF ACTIVITY Each year,
Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016
Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016 Please note that all information in this document is also disclosed in the overall report on Pfizer
Post Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
DISEASE AWARENESS. Innovative Outreach for Educating Patients and Health Care Providers
REGISTER BY JANUARY 11, 2019 AND SAVE $300! DISEASE AWARENESS CAMPAIGNS Innovative Outreach for Educating Patients and Health Care Providers February 4-5, 2019 Wyndham Philadelphia Historic District Phildelphia
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
The G8 Dementia Summit: A Giant Step Forward for Dementia
The G8 Dementia Summit: A Giant Step Forward for Dementia January 28, 2014 Mimi Lowi-Young, M.H.A, Dip Bus. Admin., FACHE, FCCHL Chief Executive Officer, Alzheimer Society of Canada Overview 1. Background
Where do we go from Here? December 7, 2013
Where do we go from Here? December 7, 2013 Jacqueline A French MD Epilepsy Center NYU School of Medicine American Epilepsy Society Annual Meeting Disclosure I have received grant funding from The Milken
Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators
Exhibitor Name Booth Number Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators 358 Accredo 947 Adako 276